fbpx
NFL to help fund research into cannabis treatment for concussions

NFL to help fund research into cannabis treatment for concussions

cannabis treatment for concussions in the NFL

Researchers from the University of Regina are getting more than $500,000 US from the National Football League to study the potential of using cannabinoids for the prevention and treatment of concussions.

Cannabinoids are the naturally occurring compounds found in the cannabis plant.

The NFL-NFLPA Joint Pain Management Committee, which said it wants to better understand and improve potential alternative pain management treatments for NFL players, put out a request for research proposals in June 2021.

The NFL said the U of R study is one of two to be awarded funding out of 106 submissions from top clinicians and researchers from around the world.

A study at the University of California San Diego that will be evaluating the effects of cannabinoids on pain and recovery from sports-related injuries in elite athletes is also receiving funding.

“We are grateful that we have the opportunity to fund these scientifically-sound studies on the use of cannabinoids that may lead to the discovery of data-based evidence that could impact the pain management of our players,” NFL chief medical officer Dr. Allen Sills said in a release.

The U of R study will be led by Patrick Neary, an exercise physiologist and professor in the faculty of kinesiology and health studies, who has been working in the area of concussion prevention and treatment for more than 15 years.

Neary said his team’s selection by the NFL was “extraordinary, overwhelming news” and “a very, very humbling experience.”

Looking for optimal CBD/THC formulation

His team will try to optimize the formulation of cannabinoids such as tetrahydrocannabinol (THC) and cannabidiol (CBD) for pain management in those suffering from post-concussion syndrome and chronic pain, and for a neuroprotective treatment for concussions.

Study Finds Cannabis Compounds Prevent Infection By Covid-19 Virus

Study Finds Cannabis Compounds Prevent Infection By Covid-19 Virus

cannabis can help with covid-19

Compounds in cannabis can prevent infection from the virus that causes Covid-19 by blocking its entry into cells, according to a study published this week by researchers affiliated with Oregon State University.

A report on the research, “Cannabinoids Block Cellular Entry of SARS-CoV-2 and the Emerging Variants,” was published online on Monday by the Journal of Natural Products.

The researchers found that two cannabinoid acids commonly found in hemp varietals of cannabis, cannabigerolic acid, or CBGA, and cannabidiolic acid, also known as CBDA, can bind to the spike protein of SARS-CoV-2, the virus that causes Covid-19. By binding to the spike protein, the compounds can prevent the virus from entering cells and causing infection, potentially offering new avenues to prevent and treat the disease.

“Orally bioavailable and with a long history of safe human use, these cannabinoids, isolated or in hemp extracts, have the potential to prevent as well as treat infection by SARS-CoV-2,” the researchers wrote in an abstract of the study.

The study was led by Richard van Breemen, a researcher with Oregon State’s Global Hemp Innovation Center in the College of Pharmacy and Linus Pauling Institute, in collaboration with scientists at the Oregon Health & Science University. Van Breeman said that the cannabinoids studied are common and readily available.

“These cannabinoid acids are abundant in hemp and in many hemp extracts,” van Breemen said, as quoted by local media. “They are not controlled substances like THC, the psychoactive ingredient in marijuana, and have a good safety profile in humans.”

Cannabinoids Effective Against New Variants

Van Breemen added that CBDA and CBGA blocked the action of emerging variants of the virus that causes Covid-19, saying that “our research showed the hemp compounds were equally effective against variants of SARS-CoV-2, including variant B.1.1.7, which was first detected in the United Kingdom, and variant B.1.351, first detected in South Africa.”

Cannabis Study Shows Occasional Use Does Not Cause Lung Damage

Cannabis Study Shows Occasional Use Does Not Cause Lung Damage

cannabis study shows cannabis use does not decrease lung function

A study, carried out by the Coronary Artery Risk Development in Young Adults (CARDIA), examined both the short- and long-term effects of cannabis on lung function.

The relationship between cannabis and lung function has been a subject of heated debate for decades. Many are aware of the harm that smoking tobacco causes to the lungs. If anything, the image of what the lungs of a smoker look like is etched in the minds of many. When it comes to smoking cannabis, obvious deductions are often made. Is there any science to back this?

Tobacco smoking has been linked to chronic obstructive pulmonary disease (COPD). [1] It is also the leading cause of preventable death in the U.S. [2,3] While cannabis smoke contains similar combustion products, it is unclear whether cannabis causes an equivalent level of destruction to the lungs.

Some studies have shown that cannabis smoke causes inflammation of the airway mucosa and triggers pulmonary symptoms such as coughing, increased phlegm production, and wheezing. [4-6] However, there are no studies that have demonstrated a decline in pulmonary function. [7]

As the legalization wave continues to sweep through the U.S, increasingly more people are smoking cannabis. Any adverse long-term effects of cannabis on the lungs is a public health issue that requires immediate attention.

A study, carried out by the Coronary Artery Risk Development in Young Adults (CARDIA), sought to understand both the short- and long-term effects of cannabis on lung function. [8] This was compared to data collected from tobacco smokers.

Michigan Cannabis Recall May Affect $200M In Cannabis Products

Michigan Cannabis Recall May Affect $200M In Cannabis Products

Michigan cannabis regulatory agency has recalled products impacting 400 retail locations across the state

In the largest product recall since the state legalized cannabis in 2019, the Michigan cannabis regulatory agency (Marijuana Regulatory Agency) has recalled enough products to impact over 400 retail locations around the state.

While the exact amount of products that are being recalled hasn’t been specified, the Marijuana Regulatory Agency (MRA) recalled all marijuana flower product that passed safety testing at Viridis Laboratories between Aug. 10 and Nov. 16. The agency released a full list of all locations impacted by the recall after calling lab test results “inaccurate and/or unreliable” in a notice issued just before 5 p.m. on Wednesday November 17, but provided no further explanation.

The recall Michigan cannabis recall only impacts flower products

“While we strongly disagree with this decision and firmly stand by our test results, we are fully cooperating with the MRA and working closely with our customers to minimize interruptions and retest affected products at no cost,” Viridis said in a prepared statement. “We have been cleared to continue testing at both of our state-of-the-art facilities. We look forward to continuing to serve our amazing customers using the best, most cutting-edge scientific methods available so we can fulfill our mission of promoting the health and safety of patients and adult-use consumers.”

According to a notice sent out by the MRA, customers who have the recalled product should return it to the retailer they purchased it from “for proper disposal.” “Consumers with weakened immune systems or lung disease are at the highest risk for health-related incidents such as aspergillosis, which can impact lung function, if these potentially harmful products are consumed,” the agency said Wednesday evening.

All Michigan cannabis products are required to have safety labels that contain the date product passed testing and the lab where it was tested. Viridis Laboratories, founded by former Michigan state police forensic scientists, operates labs in Bay City and Lansing. The license identification numbers for Viridis labs that should appear on labels are: “SC-000009, AU-SC-000113″ and “SC-000014, AU-SC-000103.”

The MRA is giving retailers holding the defective product three options: destroy the product and send the agency proof, resubmit the products for testing, or send the products back to the original source to be retested as part of a larger batch.

Gallup Cannabis Poll: Nearly Half of U.S. Adults Have Tried Marijuana

Gallup Cannabis Poll: Nearly Half of U.S. Adults Have Tried Marijuana

nearly half of Americans have tried cannabis according to a Gallup cannabis poll

WASHINGTON, D.C. — The percentage of U.S. adults who say they have tried marijuana has ticked up to 49%, the highest Gallup has measured to date. More than 50 years ago, just 4% said they had tried the drug, but that percentage surpassed 20% in 1977, 30% in 1985 and 40% in 2015.

A much smaller proportion of U.S. adults, 12%, say they “smoke marijuana.” The percentage of current marijuana smokers has been steady in recent years, varying between 11% and 13% after increasing from the 7% Gallup initially measured in 2013.

Gallup cannabis poll shows nearly half of Americans have tried cannabis

The results are based on Gallup’s annual Consumption Habits poll, conducted July 6-21.

Generational patterns explain the increase in marijuana experimentation over the last five decades. The oldest Americans living today, those born before 1945 whom Gallup calls “traditionalists,” are much less likely than those in other birth cohorts to have tried marijuana, with just 19% saying they have done so. That compares with about half of millennials (51%), Generation Xers (49%) and baby boomers (50%).

These generational figures are based on combined data from the 2015-2021 Consumption Habits surveys. Gallup does not yet have sufficient data to provide reliable estimates for Generation Z, the oldest of whom are 24 years old now.

Comparing the most recent generational figures with data from the 1980s and 1990s finds little change in the rate of marijuana experimentation among baby boomers and Gen X. Combined data from the 1985 and 1999 Gallup polls shows that 44% of members of Gen X and 50% of baby boomers had tried marijuana as of then.

During those years, a lower proportion of traditionalists than today had tried marijuana (10%). The increase in that group today compared with the 1980s and 1990s probably reflects the dying off of many of the oldest members of that generation, who were much less likely than younger traditionalists to have tried marijuana.

Read Full Study on Gallup